Clinical Trial Update: Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the pharmacokinetics and pharmacodynamics of rifaximin novel formulations in sickle cell disease has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: Bausch Health Americas, Inc. | Conditions: Sickle Cell Disease | Phase 2 | Status: COMPLETED | Results posted: 2024-09-19